AU2667901A - Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors - Google Patents

Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors

Info

Publication number
AU2667901A
AU2667901A AU26679/01A AU2667901A AU2667901A AU 2667901 A AU2667901 A AU 2667901A AU 26679/01 A AU26679/01 A AU 26679/01A AU 2667901 A AU2667901 A AU 2667901A AU 2667901 A AU2667901 A AU 2667901A
Authority
AU
Australia
Prior art keywords
vectors
cells
immortalized
immortalizing
dividing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26679/01A
Other languages
English (en)
Inventor
Teresa Occhiodoro
Patrick Salmon
Didier Trono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Geneve
Original Assignee
Universite de Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Geneve filed Critical Universite de Geneve
Publication of AU2667901A publication Critical patent/AU2667901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU26679/01A 1999-11-25 2000-11-24 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors Abandoned AU2667901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99123498 1999-11-25
EP99123498A EP1103615A1 (en) 1999-11-25 1999-11-25 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
PCT/EP2000/011723 WO2001038548A2 (en) 1999-11-25 2000-11-24 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors

Publications (1)

Publication Number Publication Date
AU2667901A true AU2667901A (en) 2001-06-04

Family

ID=8239461

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26679/01A Abandoned AU2667901A (en) 1999-11-25 2000-11-24 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors

Country Status (6)

Country Link
US (1) US20090142841A1 (https=)
EP (2) EP1103615A1 (https=)
JP (1) JP2003514565A (https=)
AU (1) AU2667901A (https=)
CA (1) CA2389667A1 (https=)
WO (1) WO2001038548A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
EP2134852A4 (en) 2007-03-13 2010-04-28 Nat Jewish Health PROCESS FOR THE PRODUCTION OF ANTIBODIES
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
ES2525411T3 (es) * 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
JP2013511275A (ja) 2009-11-18 2013-04-04 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 組織再生を誘導する方法
JP5863338B2 (ja) * 2011-08-25 2016-02-16 株式会社東芝 プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット
WO2013057164A1 (en) 2011-10-18 2013-04-25 Sarl Endocells Production of a human beta cell line from an early post natal pancreas
JP6285930B2 (ja) 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
WO2014109696A1 (en) * 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
CN103468746B (zh) * 2013-09-28 2015-03-04 青岛麦迪赛斯生物科技有限公司 一种肿瘤细胞系的构建方法
WO2017194711A1 (en) 2016-05-11 2017-11-16 Animal Cell Therapy - Act Production of a canine beta cell line from an immature pancreas
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
WO2019092135A1 (en) 2017-11-08 2019-05-16 Animal Cell Therapy - Act Production of canine pancreatic islets from an immature pancreas
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN111154807B (zh) * 2020-01-17 2023-03-24 山东农业大学 一种分泌型的崂山奶山羊乳腺上皮细胞系的构建方法
WO2022066937A1 (en) * 2020-09-23 2022-03-31 Regents Of The University Of Minnesota Immortalized keratinocytes, lentivirus for keratinocyte immortalization, and methods of use
JP7805590B2 (ja) * 2020-11-06 2026-01-26 株式会社Trans Chromosomics 可逆的不死化細胞の製造方法
KR102456805B1 (ko) * 2020-12-02 2022-10-24 충북대학교 산학협력단 불멸화 개줄기세포 또는 이의 엑소좀풍부배양액을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물
KR102572595B1 (ko) * 2020-12-02 2023-08-31 충북대학교 산학협력단 불멸화 고양이줄기세포 또는 이의 엑소좀풍부배양액을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물
CN112941033A (zh) * 2021-03-11 2021-06-11 深圳市人民医院 永生化饲养层细胞株的构建方法、永生化饲养层细胞株及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686306A (en) * 1992-05-13 1997-11-11 Board Of Regents, The University Of Texas System Methods and reagents for lengthening telomeres
US5919997A (en) * 1993-11-18 1999-07-06 Cold Spring Habor Labortary Transgenic mice having modified cell-cycle regulation
US5729597A (en) * 1995-05-16 1998-03-17 At&T Corp Service and information management system for a telecommunications network
US5629159A (en) * 1995-06-07 1997-05-13 California Institute Of Technology Immortalization and disimmortalization of cells
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ES2319238T3 (es) * 1996-07-01 2009-05-05 Gemin X Pharmaceuticals Canada Inc. Composiciones para modular la longitud de los talomeros.
EP0970201A1 (en) * 1996-09-17 2000-01-12 The Salk Institute For Biological Studies Retroviral vectors capable of transducing non-dividing cells
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
CA2304983A1 (en) * 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
WO1999035243A2 (en) * 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
PT1076715E (pt) * 1998-05-13 2007-10-26 Genetix Pharmaceuticals Inc Células empacotadoras lentivirais

Also Published As

Publication number Publication date
WO2001038548A3 (en) 2001-10-18
JP2003514565A (ja) 2003-04-22
US20090142841A1 (en) 2009-06-04
EP1103615A1 (en) 2001-05-30
CA2389667A1 (en) 2001-05-31
EP1244798A2 (en) 2002-10-02
WO2001038548A2 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
AU2667901A (en) Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
NZ513598A (en) Immortalized cell lines and methods of making the same
AU4831497A (en) Immortalized cells and uses therefor
AU2961600A (en) Electroactive material for secondary batteries and methods of preparation
AU4965799A (en) Bioreactor and cell culturing processes using the bioreactor
AU3478100A (en) Rapid determination of present and potential battery capacity
AU1824600A (en) Low oxygen culturing of cells
GB9900396D0 (en) Arrangements of electrochemical cells
AUPO917297A0 (en) Charging of batteries
AU9397098A (en) Methods and cell line useful for production of recombinant adeno-associated viruses
AU2959899A (en) Runner of umbrella
AU9582398A (en) Methods and devices for the long-term culture of hematopoietic progenitor cells
AU6627694A (en) Solid electrolyte and batteries
AU1236801A (en) Activation of hcv-specific t cells
AU3146400A (en) Source of current with series connected cells
AU6107099A (en) Mammalian artificial chromosomes and uses thereof
AU3420700A (en) Arrangement of electrochemical cells
AU6162199A (en) Reversibly immortalized hepatocytes and methods of use
AU6091600A (en) Mammalian cells expressing desaturases and elongases
GB9708526D0 (en) Eukaryotic gene expression cassette and uses thereof
AU5331796A (en) Vectors for the transfection of eucaryotic cells, their use and target cells transfected thereby
AU2998300A (en) Genetically altered mesenchymal stem cells and methods of use thereof
IL121789A0 (en) Inhibiting the growth of mammalian cells
AU2295201A (en) Spore-like cells and uses thereof
AU4081997A (en) Immortalized human hepatic cell line

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase